Recruitment of a sufficiently large number of participants into clinical trials can be a challenge in multiple therapeutic areas, and this has become particularly true for multiple sclerosis trials. For many reasons, the protocols for these trials have become very complex, and hence demanding on participants. A central difficulty in recruitment is identifying eligible patients willing to participate in these studies when there are already a number of approved disease-modifying therapies available to them. This White Paper therefore proposes mitigations strategies to address recruitment challenges.